138 related articles for article (PubMed ID: 22356659)
1. Control of intra-oesophageal pH in patients with Barrett's oesophagus on omeprazole-sodium bicarbonate therapy.
Gerson LB; Mitra S; Bleker WF; Yeung P
Aliment Pharmacol Ther; 2012 Apr; 35(7):803-9. PubMed ID: 22356659
[TBL] [Abstract][Full Text] [Related]
2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
3. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Gerson LB; Shetler K; Triadafilopoulos G
Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
[TBL] [Abstract][Full Text] [Related]
4. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
[TBL] [Abstract][Full Text] [Related]
5. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
6. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
Ortiz A; MartÃnez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
[TBL] [Abstract][Full Text] [Related]
7. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
8. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Garrean CP; Zhang Q; Gonsalves N; Hirano I
Am J Gastroenterol; 2008 Jul; 103(7):1631-7. PubMed ID: 18557714
[TBL] [Abstract][Full Text] [Related]
9. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor influence on reflux in Barrett's oesophagus.
Smythe A; Troy GP; Ackroyd R; Bird NC
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):881-7. PubMed ID: 18794602
[TBL] [Abstract][Full Text] [Related]
11. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
12. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11).
Lacy BE; Chehade R; Crowell MD
Am J Gastroenterol; 2011 Sep; 106(9):1604-11. PubMed ID: 21691342
[TBL] [Abstract][Full Text] [Related]
13. Effects of omeprazole or anti-reflux surgery on lower oesophageal sphincter characteristics and oesophageal acid exposure over 10 years.
Emken BG; Lundell LR; Wallin L; Myrvold HE; Engström C; Montgomery M; Malm AR; Lind T; Hatlebakk JG;
Scand J Gastroenterol; 2017 Jan; 52(1):11-17. PubMed ID: 27593706
[TBL] [Abstract][Full Text] [Related]
14. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
15. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.
Fass R; Sampliner RE; Malagon IB; Hayden CW; Camargo L; Wendel CS; Garewal HS
Aliment Pharmacol Ther; 2000 May; 14(5):597-602. PubMed ID: 10792123
[TBL] [Abstract][Full Text] [Related]
16. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
17. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.
Katzka DA; Castell DO
Am J Gastroenterol; 1994 Jul; 89(7):989-91. PubMed ID: 8017396
[TBL] [Abstract][Full Text] [Related]
18. Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus.
Sampliner RE; Camargo L; Fass R
Am J Gastroenterol; 2002 Feb; 97(2):270-2. PubMed ID: 11866260
[TBL] [Abstract][Full Text] [Related]
19. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
